HAIC治疗全身化疗失败的不可切除的结直肠癌肝转移的疗效分析

Therapeutic effect of HAIC on unresectable liver metastases from colorectal cancer with systemic chemotherapy failure

目的探讨肝动脉持续灌注化疗(HAIC)在全身化疗失败的不可切除结直肠癌肝转移患者中的疗效观察及对生存期的影响。方法将2012年3月～2015年8月入院治疗的全身化疗失败的不可切除结直肠癌肝转移患者98例分为对照组49例与观察组49例。对照组采用全身化疗治疗,观察组采用HAIC治疗,治疗后比较两组的临床疗效及对毒副反应、生存率的影响。结果观察组采用肝动脉持续灌注化疗2周期后疗效率高于对照组(P<0.05);观察组采用肝动脉持续灌注化疗2个周期后中性粒细胞减少、血小板减少、贫血、恶心呕吐、肝脏毒性、腹泻毒副反应发生率与对照组比较,差异无统计学意义(P>0.05);观察组化疗后2个周期无瘤生存率、40个月总生存率高于对照组(P<0.05)。结论肝动脉持续灌注化疗用于全身化疗失败的不可切除结直肠癌肝转移患者中效果确切,有助于提高临床疗效,降低毒副反应发生率,提高患者生存率。

Objective To investigate the effect of continuous hepatic artery perfusion chemotherapy(HAIC) on unresectable colorectal cancer liver metastasis with systemic chemotherapy failure and its effect on survival. Methods 98 unresectable colorectal cancer liver metastasis patients with systemic chemotherapy failure from March 2012 to August 2015 were divided into the control group (n=49) and the observation group (n=49). The control group was treated with systemic chemotherapy, and the observation group was treated with HAIC. After treatment, the clinical effects and the effects of the two treatments on toxicity and survival rate were compared. Results The effective rate of the observation group was higher than that of the control group after 2 cycles of continuous hepatic artery perfusion chemotherapy (P< 0.05).The incidence of hepatotoxicity and diarrhea side effects including neutropenia, thrombocytopenia, anemia, nausea and vomiting in the observation group was not significantly different from that of the control group after 2 cycles of continuous hepatic artery perfusion chemotherapy (P>0.05). The 2-cycle tumor-free survival rate and 40-month overall survival rate in the observation group were higher than those in the control group after chemotherapy(P<0.05). Conclusion Continuous hepatic artery perfusion chemotherapy is effective in unresectable colorectal cancer liver metastasis patients with systemic chemotherapy failure, which can improve clinical efficacy, reduce the incidence of side effects and improve patient survival rate.